ArticlePDF Available

Acute hemolysis in glucose-6-phosphate dehydrogenase deficiency after coronary angiography

Authors:

Abstract and Figures

The contrast agents in current use are generally safe, however have some side reactions, can range from minor to severe, sometimes resulting in death. Nowadays, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is known as one of the most common hereditary disorders of erythrocytes, causing intravascular hemolysis. Most of patients with G-6-PD deficient are usually asymptomatic, on the other hand can present by hemolytic anemia particularly after the administration of some drugs, exposure to fava beans, infections and during diabetic acidosis. We describe here a 44-year-old man with G-6-PD deficient, who developed acute severe hemolysis after diagnostic coronary angiography.
Content may be subject to copyright.
Vol. 174 - No. 1 GAZZETTA MEDICA ITALIANA - ARCHIVIO PER LE SCIENZE MEDICHE 1
The contrast media used for radio-
logic studies are markedly hyperosmolar
and hypo-osmolar, some of them being
up to eight times the physiologic level of
300mOsm/kg of water,2 and all types of
adverse reactions are more common with
these agents, are associated with nephrotic,
less serious cardiovascular and anaphy-
lactoid reactions. We report a patient with
G-6-PD deciency who developed severe
hemolysis following administration of radi-
ographic contrast material for coronary an-
giography; we draw attention to this poten-
tial complication of angiography in patients
with G-6-PD deciency.
Case report
A 44-year-old man was admitted to cardiology
service with persistent chest pain (CCS II) and
dyspnea (NYHA II) for one month. He had type-2
diabetes for one year and denied a history of aller-
gies and drug use. The initial examination showed
a moderately obese, who was afebrile, normoten-
sive, and anicteric. Cardiac examination disclosed
a grade 2/6 pansystolic murmur at the left sternal
border. An electrocardiogram (ECG) reportedly
showed a normal sinus rhythm, with a rate 90 beats
per minute. The cardiac markers were normal. No
hepatosplenomegaly was detected. At admission his
1Cardiologyclinic
AntalyaTrainingandResearchHospital
Antalya, Turkey
????
GAZZ MED ITAL - ARCH SCI MED 2015;174:1-2
S. KÜÇÜKSEYMEN 1, G. ÇAĞIRCI 1, E. KÖKLÜ 1
I. O. YÜKSEL 1, N. BAYAR 1, M. ESIN 1, Ş. ARSLAN 1
Acute hemolysis in glucose-6-phosphate
dehydrogenase deciency after coronary angiography
The contrast agents in current use are gener-
ally safe, however have some side reactions,
can range from minor to severe, sometimes
resulting in death. Nowadays, glucose-6-phos-
phate dehydrogenase (G-6-PD) deciency is
known as one of the most common heredi-
tary disorders of erythrocytes, causing in-
travascular hemolysis. Most of patients with
G-6-PD decient are usually asymptomatic,
on the other hand can present by hemolytic
anemia particularly after the administration
of some drugs, exposure to fava beans, in-
fections and during diabetic acidosis. We de-
scribe here a 44-year-old man with G-6-PD
decient, who developed acute severe hemo-
lysis after diagnostic coronary angiography.
Key words: Hemolysis - Coronary Angiography
- Glucosephosphate Dehydrogenase Deciency -
Contrast Media.
Glucose-6-phosphate dehydrogenase
(G-6-PD) is a critical enzyme in the re-
dox metabolism of all aerobic cells. Also,
G-6-PD deciency, is the most common
hereditary enzyme deciency worldwide,
but the people with G-6-PD deciency are
usually asymptomatic, on the other hand, it
may develop an acute hemolytic state after
exposure to drugs, infections and chemi-
cals, for example, streptomycin, paraami-
nosalicylic acid, suplhonamides, acetylsali-
cylic acid, isoniazid and acetaminophen.1
Corresponding author: S. Küçükseymen, Cardiology clin-
ic, Antalya Training and Research Hospital, Varlik mahallesi,
Kazim Karabekir caddesi, Soğuksu, 07100, Antalya, Turkey.
E-mail: skucukseymen@gmail.com
Anno: 2015
Mese: ??
Volume: 174
No: 1
Rivista: GAZZETTA MEDICA ITALIANA - ARCHIVIO PER LE SCIENZE MEDICHE
Cod Rivista: GAZZ MED ITAL - ARCH SCI MED
Lavoro: 3093-GMI
titolo breve: ACUTE HEMOLYSIS IN G-6-PD DEFICIENCY AFTER CORONARY
ANGIOGRAPHY
primo autore: KÜÇÜKSEYMEN
pagine: 1-2
3093-GMI
PROOF
MINERVA MEDICA
PROFF ID.indd 1 10/09/10 14:28
2 GAZZETTA MEDICA ITALIANA - ARCHIVIO PER LE SCIENZE MEDICHE ?? 2015
KÜÇÜKSEYMEN ACUTE HEMOLYSIS IN G-6-PD DEFICIENCY AFTER CORONARY ANGIOGRAPHY
hemoglobin level was 13.6 g/dL (normal 13.5-17.3
g/dL); blood cell counts, serum bilirubin and lactate
dehyrogenase (LDH) levels were normal and fasting
blood glucose level of 128 mg/dL. Coronary angi-
ography was performed via the right femoral artery
with 6Fr Judkins catheter. Totaly thirty-eight millili-
ters of contrast material, IOPAMIRO 300 (Iopami-
dol, 61.2 g; Trometamol, 100 mg; calcium disodium
EDTA (6H2O), 39 mg; HCl pH 7.1) was injected for
total procedure. The coronary angiography revealed
normal coronary arteries (Figures 1, 2). In the two
days after the follow-up, the patient developed
generalized back pain without ant chills, rigors, or
shortness of breath. On examination, there are no
varying ndings, she was afebrile and normoten-
sive, no rash was noted and there was no bleeding
at the catheterization site, but the hemoglobin level
was found to be 10.2 g/dL; serum bilirubin and LDH
levels were slightly increased, total bilirubin 2.2 mg/
dL of which the direct component was 0.41 and
LDH was 279 U/L (normal 135-225 U/L). Abdomi-
nal and pelvic ultrasound examinations were per-
formed by radiologist and there was no evidence
of any bleeding. The following day the patient was
severely icteric, fasting blood glucose level of 108
mg/dL but otherwise felt well. Controlled laboratory
parameters and hemoglobin level was 7.0 g/d and
total bilirubin 13.1 mg/dL, serum indirect bilirubin
11.3 mg/dL, LDH 943 U/L. We headed to a hematol-
ogist for a consult to determine why these parame-
ters increased. Peripheral blood smear, haptoglobin
level and coombs tests were made. All coombs tests
were negative, but in peripheral blood smear heinz
bodies and spherocytosis were seen in red blood
cells (gure 3.) and haptoglobin level was 9.8 mg/
dL (normal 16-200 mg/dL), reticulocyte count 5.1%
and hemolytic anemia was diagnosed. G-6-PD de-
ciency test was performed and 2.16 U/g Hb values
were found (normal 4.60-13.50 U / g Hb). Treated
with 3 units of leukocyte reduced packed RBCs
with the diagnosis of G6PD deciency. Hemoglobin
level increased to 12.1 g/dL and total and indirect
bilirubin improved 3.14 mg/d Land 0.98 mg/dL, re-
spectively. No trace of hemolysis was found. Patient
found to be stable and discharged subsequently.
Discussion
Hemolytic anemia is a form of anemia due
to hemolysis in which the red blood cells
are destroyed faster than the bone marrow
can produce them. There are two types of
hemolytic anemia: intrinsic and extrinsic.3
Intrinsic (hereditary) hemolytic anemias
can be due to defective red cell metabo-
lism as in G-6-PD deciency and pyruvate
kinase deciency, defects in hemoglobin
production as in thalassemia, sickle-cell dis-
ease and congenital dyserythropoietic ane-
mia, defects of red blood cell membrane
production as in hereditary spherocytosis
and hereditary elliptocytosis, on the other
hand extrinsic hemolytic anemias may be
caused by immune-mediated causes, drugs
and other miscellaneous causes.4.
G-6-PD deciency is the most common
of all clinically signicant enzyme defects:
more than 200 million people are G-6-PD
decient around the world.5 The best char-
acterized exogenous triggers of hemoly-
sis in G-6-PD decient, several factors are
apart from infection, fava beans and drug
induced hemolytic attack in a G-6-PD de-
ciency.6 G-6-PD deciency is diagnosed by
a quantitative spectrophotometric analysis
or a rapid uorescent spot test detecting the
generation of NADPH from NADP. Howev-
er, G-6-PD deciency disease is generally
suspected from routine laboratory analysis
as complete blood count, liver enzymes and
lactate dehydrogenase and clinical features
of patients, and then is investigated.
Contrast materials, also called contrast
agents or contrast media, are used to im-
Figure 2.—Normal right coronary artery angiogram. Figure 1.—Normal left anterior descending artery (LAD),
and circumex artery (Cx) angiogram.
PROOF
MINERVA MEDICA
PROFF ID.indd 1 10/09/10 14:28
Vol. 174 - No. 1 GAZZETTA MEDICA ITALIANA - ARCHIVIO PER LE SCIENZE MEDICHE 3
ACUTE HEMOLYSIS IN G-6-PD DEFICIENCY AFTER CORONARY ANGIOGRAPHY KÜÇÜKSEYMEN
contrast agent in our clinic.
In literature, there are many cases drug-
induced hemolytic anemia, additionally
these drugs are therapeutic or symptomatic
drugs. However contrast agent, which we
provide, is only for diagnostic and hemoltik
severe anemia associated with a substance
like this agent, such cases are very rare in
the literature. Previously, in the literature
in patients with sickle cell anemia, hemo-
lytic anemia have been reported depend-
ing on the contrast agent, but in that case,
hemolytic anemia may have arisen due to
infection.10 They have used MD-76 con-
trast agent in their case, so a hyperosmolar
agent, on the other hand, our case is the
rst in the literature, acute severe hemolysis
occurred after contrast agent in G-6-PD de-
cient patient.
In our case, we have used a hypo-osmo-
lar contrast agent, and after the procedure,
we encountered a acute severe hemolysis.
As a result, in the differential diagnosis of
hemolytic anemia, no matter what type of
contrast agents should be considered.
Conclusions
In such a complication after coronary an-
giography, if it is compatible with the nd-
ings of acute hemolysis, G-6-PD deciency
should always bring to mind and advise
prove pictures of the inside of the body
produced by x-rays, computed tomography
(CT), magnetic resonance (MR) imaging,
and ultrasound.7 Radiocontrast agents are
typically iodine or barium compounds. Bar-
ium sulfate is mainly used in the imaging of
the digestive system. Iodine contrast agents
are used for angiography (arterial investiga-
tions), venography (venous investigations),
VCUG (voiding cystourethrography), HSG
(hysterosalpingogram) and IVU (intrave-
nous urography). Modern iodinated contrast
agents are generally well tolerated; adverse
reactions ranging from mild to severe do
occur but severe reactions are very uncom-
mon, the major side effects of radiocontrast
are anaphylactoid reactions and contrast-
induced nephropathy.8 Hyperosmolar and
hypo-osmolar solutions are type of ionic
contrast agents. Many of the side effects are
due to the hyperosmolar solution being in-
jected. Hypoosmolar contrast agents are less
likely to induce side effects than hyper-os-
molar agents and these are Iopamidol, Ioxi-
lan, Iohexol, Iopromide and Iodixanol.9
In our case of patient had type 2 diabe-
tes, but did not use any drugs and there was
also no family history. Additionally he nev-
er before had not been sufcient to blood
transfusion. Events that occurred in our
case, jaundice and acute severe hemolysis
occurred two days after coronary angiog-
raphy. He did not receive any drug except
Figure 3.—Heinz bodies and spherocytosis were seen in peripheral blood smear.
PROOF
MINERVA MEDICA
PROFF ID.indd 1 10/09/10 14:28
4 GAZZETTA MEDICA ITALIANA - ARCHIVIO PER LE SCIENZE MEDICHE ?? 2015
KÜÇÜKSEYMEN ACUTE HEMOLYSIS IN G-6-PD DEFICIENCY AFTER CORONARY ANGIOGRAPHY
6. Pamba A, Richardson ND, Carter N, Duparc S, Premji
Z, Tiono AB, et al. Clinical spectrum and severity of
hemolytic anemia in glucose 6-phosphate dehydro-
genase-decient children receiving dapsone. Blood
2012;120:4123-33.
7. Bettmann MA. Angiographic contrast agents: conven-
tional and new media compared. AJR Am J Roentge-
nol 1982;139:787-94.
8. Bottinor W, Polkampally P, Jovin I. Adverse Reactions
to Iodinated Contrast Media. Int J Angiol 2013;22:149-
54.
9. Wittbrodt ET1, Spinler SA. Prevention of anaphy-
lactoid reactions in high-risk patients receiving
radiographic contrast media. Ann Pharmacother
1994;28:236-41.
10. Rao AK, Thompson R, Durlacher L, James F. Angi-
ographic contrast agent-induced acute hemolysis in a
patient with hemoglobin SC disease. Arch Intern Med
1985;145:759-60.
Conicts of interest.—The authors certify that there is no
conict of interest with any nancial organization regarding
the material discussed in the manuscript.
Received on July 9, 2014.
Accepted for publication on January 8, 2015.
that newer contrast agents with hypo-osmo-
lar ones need to be carefully evaluated for
radiologic studies in patients with G-6-PD
decient disease.
References
1. Chhabra A, Raj D, Choudhary PN, Grover A. Inter-
esting case of G6PD deciency anemia with severe
hemolysis. Asian J Transfus Sci 2013;7:147-8.
2. Perillie PE, Ebstein FH. Sickling phenomenon pro-
duced by hypertonic solutions: A possible explana-
tion for the hyposthenuria of sicklemia. J Clin Invest
1963;42:570-80.
3. Edward R. Evans: Diagnosis of the hemolytic ane-
mias. Calif Med 1951;75:271-5.
4. Schwartz RS. Autoimmune and intravascular hemolyt-
ic anemias. In: Goldman L, Schafer AI, editors. Cecil
Medicine. 24th edition. Philadelphia, PA: Saunders
Elsevier; 2011: chap. 163.
5. Beutler E. Glucose 6 phosphate dehydrogenase de-
ciency. N Engl J Med 1991;324:169-74.
PROOF
MINERVA MEDICA
PROFF ID.indd 1 10/09/10 14:28
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Severe hemolysis was observed in a critically ill patient with G6Pd deficiency where the causative trigger could not be identified. We describe one young patient with severe hemolysis treated with two cycles of plasmapheresis which proved to be an effective tool in the treatment. The patient presented with diffuse pain abdomen, vomiting, yellowish discoloration of sclera and skin and acute breathlessness. Hemoglobin 5.4 mg/dl and total (T) serum bilirubin 17.08 mg/dl: Direct (D) 4.10 mg/dl and Indirect (I) 12.98 mg/dl. Subsequently patient started passing black color urine. As the patient developed severe hemolysis and the trigger agent of hemolysis was unknown, two cycles of plasmapheresis were performed with the aim to remove unknown causative agent. Consequently no trace of hemolysis was found and patient stabilized. Plasmapheresis can be used to treat G6PD deficient patients with severe hemolysis due to unidentified trigger agent.
Article
Full-text available
Drug-induced acute hemolytic anemia (AHA) led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In two clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for three days), 95 G6PD-deficient hemizygous boys, 24 G6PD-deficient homozygous girls and 200 girls heterozygous for G6PD deficiency received this agent. In the first two groups, there was a maximum decrease in hemoglobin averaging -2.64 g/dL (range -6.70 to +0.30 g/dL); significantly greater than for the comparator group receiving artemether-lumefantrine (adjusted difference -1.46 g/dL; 95% confidence interval -1.76, -1.15). Hemoglobin concentrations were decreased by ≥40% versus pre-treatment in 24/119 (20.2%) of the G6PD-deficient children; 13/119 (10.9%) required blood transfusion. In the heterozygous girls, the mean maximum decrease in hemoglobin was -1.83 g/dL (range +0.90 to -5.20 g/dL); 1/200 (0.5%) required blood transfusion. All children eventually recovered. All the G6PD-deficient children had the G6PD A- variant, i.e. mutations V68M and N126D. Drug-induced AHA in G6PD A- subjects can be life-threatening, depending on the nature and dosage of the drug trigger. Therefore, contrary to current perception, in clinical terms the A- type of G6PD deficiency cannot be regarded as mild. Trial registration: www.clinicaltrials.gov #NCT00344006 and #NCT00371735.
Article
The use of iodinated contrast agents for angiography dates back to the 1920s. With over 75 million contrast-requiring procedures performed annually worldwide, it is important to understand the risk factors, pathogenesis, diagnosis, prevention, and treatment of adverse reactions caused by iodinated contrast media (ICM). As contrast media have evolved from ionic, high-osmolality to nonionic, low-osmolality formulations the risk of reactions has decreased over time; however, no pretreatment protocol has been shown to eliminate all repeat reactions. Clinical alertness and early recognition of adverse reactions is of paramount importance and key for appropriate management of these patients. In this article, we review the most recent literature regarding adverse reactions to ICM and provide an insight into the pathogenesis, clinical presentation, pretreatment, and management of contrast-related reactions.
Article
Radiographic contrast media used for angiographic procedures are hyperosmolar and induce sickling in vitro of erythrocytes from patients with sickle cell disorders. We treated a 51-year-old black woman with hemoglobin SC disease, but without a history of painful crises, who developed severe intravascular hemolysis and pulmonary infiltrates following administration of a contrast agent for coronary angiography and ventriculography. This case emphasizes the potential for severe complications following administration of the currently available contrast agents to patients with sickle cell disease. We suggest that newer contrast agents with lower osmolality than the commonly used ones need to be carefully evaluated for radiologic studies in patients with sickle cell disease.
Article
The contrast agents in current use are generally safe, but have certain undesirable side effects. These can be divided into four major areas: systemic reactions, cardiac effects, renal effects, and general vascular effects. For the most part, particularly in regard to cardiac and vascular manifestations, adverse effects are due to a combination of hypertonicity of the ionic contrast agent to blood, calcium binding, and direct chemical toxicity of the specific anion used. There have been many attempts to develop new agents, with a primary aim of lessening the adverse effects. Several of these compounds have undergone extensive experimental evaluation and are currently being used in clinical trials. All of these new agents have lower tonicity than conventional media at the same iodine content. They also appear to bind calcium less. Compared to conventional agents, these new compounds have less effect on the vessel wall and probably on blood coagulation, less effect on renal function, which is particularly important in patients with compromised renal function, and less effect on hemodynamic and electrocardiographic parameters. They also seem to cause much less discomfort during peripheral arteriography than current contrast media. These new agents may be commercially available by 1984 and probably will be significantly more expensive than conventional agents. It is not yet clear, because of higher cost, whether these agents will be used for all patients, or only for patients at particular risk of side effects from conventional contrast media.
Article
To review various pretreatment regimens for the prophylaxis of anaphylactoid reactions to radiographic contrast media (RCM) in high-risk patients. The proposed etiologies and risk factors for such reactions are also reviewed. A MEDLINE search of the English-language literature was used to identify pertinent human studies and reviews. All studies comparing pretreatment regimens for anaphylactoid reactions to RCM were reviewed as well as studies comparing the incidence of anaphylactoid reactions between lower and higher osmolar RCM. The two types of reactions to RCM are dose-independent, unpredictable anaphylactoid (pseudoallergic or idiosyncratic) reactions and the dose-dependent, predictable physicochemical (intrinsic, nonidiosyncratic) reactions. Prophylaxis of the former type is targeted at stemming the effects of certain chemical mediators, primarily histamine. The use of lower osmolar RCM is associated with a lower incidence of anaphylactoid reactions compared with higher osmolar RCM, but is significantly more expensive. Risk factors for such reactions are a history of previous anaphylactoid reaction to RCM, asthma, and reaction to skin allergens or penicillin. Discontinuation of any beta-blockers before the procedure is suggested. Pretesting patients with a small amount of RCM has little predictive value for an anaphylactoid reaction. Various pretreatment prophylactic regimens have been studied. Almost all included a corticosteroid to target the inflammatory response and a histamine1 (H1)-antagonist to blunt the effects of histamine. In some clinical trials, ephedrine was added for bronchodilation and cimetidine for its antagonism at the histamine2-receptor. The few controlled clinical trials that have been performed show the combination of prednisone and diphenhydramine to be most beneficial in preventing anaphylactoid reactions to RCM. The addition of ephedrine or cimetidine to a pretreatment regimen remains controversial. More controlled clinical studies comparing various pretreatment regimens for high-risk patients need to be performed, especially in patients receiving lower osmolar RCM. Recommendations for high-risk patients who must receive RCM include use of a lower osmolar agent, pretreatment with a corticosteroid and an H1-antagonist, discontinuation of beta-blockers if the patient is taking any, and bedside availability of appropriate medications and equipment to treat anaphylaxis.
Article
Classification of the varieties of hemolytic anemia is based upon whether hemolysis is due to inherent defects within the erythrocyte or to extracellular factors. CONFIRMATION OF DIAGNOSIS IN CASES IN WHICH THE DISEASE IS CLINICALLY SUSPECTED IS MADE UPON THE BASIS OF THE FOLLOWING LABORATORY DATA: Hyperbilirubinemia giving an indirect van den Bergh reaction, observation of typical factors in a smear of the blood, a reactive bone marrow, increased urobilinogen in stools and urine, and absence of bilirubinuria. Differentiation of the different types depends upon determination of altered fragility of erythrocytes as indicated by tests of resistance to heat, acid, and mechanical and osmotic stimuli, and upon the identification of an antibody. The importance of detecting antibodies demonstrable in acid serum is mentioned. In a majority of cases, acquired hemolytic anemia is caused by antibodies, malignant disease, or toxic agents.